Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912511 | 0.93 | PDE4B (0.52) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL30912524 | 0.93 | PDE4B (0.52) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL20695969 | 0.91 | KDM1A (0.53) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL5971118 | 0.87 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL5971305 | 0.87 | GPR119 (0.66) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL5971017 | 0.87 | PDE4B (0.67) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL2749734 | 0.87 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL31203077 | 0.86 | PDE4B (0.49) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4476474 | 0.86 | PDE4B (0.53) | PDE4BPDE4DPDE4APDE4CNR1H2 | |
| SCHEMBL5864903 | 0.86 | PDE4B (0.54) | PDE4BPDE4DPDE4APDE4CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| EP-1245564-B1 | BENZAMIDINE DERIVATIVES | SANKYO CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| EP-1636195-A1 | QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106308-A1 | QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-5580883-A | INHIBITING DEGENERATION AND NECROCYTOSIS OF CEREBRAL NERVE CELLS CAUSED BY OXIDATIVE STRESS INDUCING GLUTAMIC ACID IN MAMMALS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-03 | — | — | US | disclosed |
| EP-0449195-B1 | Aminobenzene compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0449195-A2 | Aminobenzene compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, ERBB4 | PDE4B 4354/4885PDE4D 4492/4885PDE4A 4364/4885 |
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | PDE4B 3861/4885PDE4D 3926/4885PDE4A 3764/4885 |
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | PDE4B 3983/4885PDE4D 4062/4885PDE4A 3917/4885 |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | PDE4B 1462/4885PDE4D 1708/4885PDE4A 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.